It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The multi-subunit translation initiation factor eIF2B is a control node for protein synthesis. eIF2B activity is canonically modulated through stress-responsive phosphorylation of its substrate eIF2. The eIF2B regulatory subcomplex is evolutionarily related to sugar-metabolizing enzymes, but the biological relevance of this relationship was unknown. To identify natural ligands that might regulate eIF2B, we conduct unbiased binding- and activity-based screens followed by structural studies. We find that sugar phosphates occupy the ancestral catalytic site in the eIF2Bα subunit, promote eIF2B holoenzyme formation and enhance enzymatic activity towards eIF2. A mutant in the eIF2Bα ligand pocket that causes Vanishing White Matter disease fails to engage and is not stimulated by sugar phosphates. These data underscore the importance of allosteric metabolite modulation for proper eIF2B function. We propose that eIF2B evolved to couple nutrient status via sugar phosphate sensing with the rate of protein synthesis, one of the most energetically costly cellular processes.
The activity of translation initiation factor eIF2B is known to be modulated through stress-responsive phosphorylation of its substrate eIF2. Here, the authors uncover the regulation of eIF2B by the binding of sugar phosphates, suggesting a link between nutrient status and the rate of protein synthesis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Calico Life Sciences LLC, South San Francisco, USA
2 Calico Life Sciences LLC, South San Francisco, USA; Loxo Oncology at Lilly, South San Francisco, USA
3 Research & Development, AbbVie, North Chicago, USA (GRID:grid.431072.3) (ISNI:0000 0004 0572 4227)
4 University of Utah School of Medicine, Department of Biochemistry, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096)
5 Calico Life Sciences LLC, South San Francisco, USA (GRID:grid.431072.3)
6 University of Utah School of Medicine, Department of Biochemistry, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096); University of Utah School of Medicine, Howard Hughes Medical Institute, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096)
7 Calico Life Sciences LLC, South San Francisco, USA (GRID:grid.223827.e)